SlideShare a Scribd company logo
1 of 22
Biovigilance
Dr Bronwen Harvey
Director, Signal Investigation Unit
Pharmacovigilance and Special Access Branch, TGA
Biotherapeutics Association of Australasia 2016 AGM, TGA Workshop & Education Session
13 October 2016
Outline
• What are biologicals?
• Regulatory framework for biologicals
• What is biovigilance?
• Responsibilities of sponsors of biologicals
– reporting adverse events
– recalls
• Sponsors’ biovigilance systems
• TGA process
– development of draft guidance, consultation, finalisation of guidance
– regulatory aspects
• Questions and discussion
Biovigilance 1
What are biologicals?
Short
definition
=
human
tissue and
cell-derived
products
Definition of a biological in the TG Act (Part 3-2A–Biologicals)
32A Meaning of biological
(1) Subject to subsection (3), a biological is a thing that:
(a) either:
(i) comprises, contains or is derived from human cells or human tissues; or
(ii) is specified under subsection (2); and
(b) is represented in any way to be, or is, whether because of the way in which it is presented or for
any other reason, likely to be taken to be:
(i) for use in the treatment or prevention of a disease, ailment, defect or injury affecting persons;
or
(ii) for use in making a medical diagnosis of the condition of a person; or
(iii) for use in influencing, inhibiting or modifying a physiological process in persons; or
(iv) for use in testing the susceptibility of persons to a disease or ailment; or
(v) for use in the replacement or modification of parts of the anatomy in persons.
[In addition, the Secretary can specify things to be or not to be biologicals by instrument]
Biovigilance 2
Regulatory framework for biologicals
• Provides the legislative basis for the regulation of human tissue and cell-derived products that are
supplied in, or exported from, Australia.
• Legislation commenced May 2011 – transition period (3 years+)
• Information on TGA website at https://www.tga.gov.au/regulatory-framework-biologicals
• Australian Regulatory Guidelines for Biologicals at https://www.tga.gov.au/publication/australian-
regulatory-guidelines-biologicals-argb
• Not biological medicines
• Similar, but not identical, to the EMA’s Advanced Therapy Medicinal Products (ATMPs) which are
medicines for human use that are based on genes or cells
Biovigilance 3
What is biovigilance?
• The science and activities relating to the detection, assessment, understanding
and prevention of adverse events or any other problems related to biologicals
• Therapeutic product vigilance in Australia
 Pharmacovigilance
 Medical devices vigilance
 Biovigilance
• Includes quality issues
• Other terms - post-market monitoring / surveillance
• Systematic collection and analysis of information to improve patient safety
Biovigilance 4
Responsibilities of sponsors of biologicals
• Therapeutic Goods Act 1989 and Therapeutic Goods Regulations 1990
• Sponsors of biological products on the Australian Register of Therapeutic Goods
(ARTG) must report to the TGA
 Serious threat to public health = 48 hours
 Serious adverse event = 10 calendar days
 Near serious adverse event = 30 calendar days
• This terminology used as biologicals legislation was based on devices legislation
• All classes of biologicals
• Uniform Recall Procedure for Therapeutic Goods
 Recalls, quality defects, contaminated biologicals = as soon as possible
Biovigilance 5
Biovigilance guidance
• Draft guidance has been developed based on the TGA pharmacovigilance and
medical device vigilance guidance
• Also based on relevant pharmacovigilance guidance, standards and terminology
– European Medicine Agency (EMA) Good Pharmacovigilance Practice (GVP)
– International Conference on Harmonisation of Technical Requirements
Technical Requirements for Pharmaceuticals for Human Use (ICH)
Biovigilance 6
Adverse events (1)
• Any undesirable medical event that occurs in temporal relationship with (during or
after) the use of a biological product
– symptom, sign (e.g. abnormal laboratory finding), disease or injury
– at least a reasonable possibility of a causal relationship between the use of the biological
and the event
• Serious adverse event
– an event or occurrence that led to a death or serious deterioration in the state of health of a
patient, a user of the biological or another person
• Near serious adverse event
– an event or occurrence that, if it occurred again, might lead to the death or serious
deterioration in the state of health of a patient, a user of the biological or another person
Biovigilance 7
Adverse events (2)
• AEs may relate to the biological itself or any aspect of the biological
– Solutions
– Excipients
– other substances or materials
– Packaging
– delivery systems
Biovigilance 8
Adverse events (3)
• Potential for AEs depends on
– origin of the biological (autologous or allogeneic)
– ability of cells constituting a biological to proliferate or differentiate
– ability of the biological to initiate an immune response
– life span of the biological in vivo
– site and mode of administration
– type and level of cell manipulation during production
– storage time and conditions
– out-of-specification findings identified during in-process testing of the biological
Biovigilance 9
Serious adverse events (SAEs)
• An adverse event for which one or more of the following is true
– results in death
– is life-threatening
– requires inpatient hospitalisation
– prolongs existing hospitalisation
– results in persistent or significant disability or incapacity, including permanent impairment of
a body function or permanent damage to a body structure
– necessitates medical or surgical intervention to prevent permanent impairment of a body
function or permanent damage to a body structure
– is a congenital anomaly or birth defect
– is a medically important event
Biovigilance 10
How to report adverse events
• Minimum data for a valid report
– an identifiable patient (but do not send name to the TGA
– one or more suspected biological or delivery system or other aspect of a biological
– one or more suspected adverse events (events with a reasonable possibility of causal
relationship)
– one or more identifiable reporters
• Only adverse events that have occurred in Australia
• Provide as much information as possible to facilitate assessment of the AE
• Range of reporting formats available, including direct data entry online
– More information on TGA website at https://www.tga.gov.au/reporting-problems
– Will develop specific formats for biologicals – currently use either medicines or medical devices
reporting processes
Biovigilance 11
Examples
• Some reports of tissue related adverse events received over the past 3 years
– Pulmonary heart valve – leaflet tear and bleeding
– Heart valve – sterility concerns – recipient had an infection
– Bone (femoral head) – several reports relating to new information about the
donor such as malignancy
Biovigilance 12
Serious threat to public health
• Any identified safety issue which may change the benefit-risk assessment of the product and
require action to eliminate or reduce that risk, such as
– a report of an unexpected or previously unknown serious or near serious adverse event
– a change in the nature, severity or frequency of expected (known) adverse events
– the identification of previously unknown risk factors
– the transmission of an infectious agent, including reactivation of any viral vector
– a signal of a possible teratogenic effect
– a signal of possible tumorigenicity
– unexpected lack of efficacy
– issues related to the raw materials used in the biological
– issues related to the delivery system used for the biological
– issues due to misinformation in the product documentation
– issues related to use outside the approved indication or intended use
Biovigilance 13
How to report a serious threat to public health
• In writing and sent by email to the Signal Investigation Coordinator
(si.coordinator@tga.gov.au)
– Subject line = ‘Urgent – serious threat to public health – [descriptor: name or number of
biological, name of sponsor, or some other descriptor]’
– describe the evidence for the threat
– indicate the action that the sponsor is proposing to take to eliminate or reduce the risk
 the action may relate to conditions of inclusion in the ARTG including amendments to the
label or the product information or any other change
– clearly identify the person in Australia who is taking responsibility on behalf of the sponsor for
the accuracy and veracity of the information in the report
– include contact details of the person reporting on behalf of the sponsor, preferably the
nominated biovigilance contact person
Biovigilance 14
Recalls and quality issues
• Notify suspected or confirmed quality defects and contaminated or counterfeit
biological products to the TGA with the least possible delay
– Uniform Recall Procedure for Therapeutic Goods (URPTG)
 New version will include biologicals
• May be necessary to implement urgent measures to protect public health
– for tissues usually “Hazard Alerts” but may involve a recall
• Use the Human blood and tissues recall report form or phone TGA Recalls on
1800 020 512
– see Contact details for enquiries about product recalls on the TGA website at
https://www.tga.gov.au/product-recalls#contacts
Biovigilance 15
System for Australian Recall Actions (SARA) - Biologicals
Recall action
commencement date
Product name / description Reason for recall action
Recall action
17/06/2014 Pulmonary Valve Allograft Staph epidermis isolated from nutrient broth
Hazard Alert
24/04/2014 Corneo-scleral Disc (Normothermic) Potentially untraceable microbiology results
Hazard Alert
31/05/2013 Bone Fragments - Milled irradiated femoral
head
At 2nd donation, donor found to have mantle cell lymphoma
Hazard Alert
17/04/2013 Pulmonary Valve Transplant Positive microbiological culture from implant tissue culture
Hazard Alert
19/03/2013 RegenerOss Allograft Block Max/Mand
Blocks
Assays used to test donors for HBsAG and Hep C not licensed for donor testing
Hazard Alert
1/03/2013 Bone Fragments - Milled irradiated femoral
head
Donor melanoma removed 10 months after donation
Hazard Alert
15/02/2013 Bone Unprocessed - Whole femoral head
non-irradiated allograft
Donor diagnosed with oesophageal cancer
Hazard Alert
22/01/2013 Corneal Grafts Multiple myeloma found later in bones from same donor
Hazard Alert
8/01/2013 QHVB Pulmonary Allograft Conduit (Human
cardiovascular tissue)
Retained samples showed positive microbial growth
Hazard Alert
Biovigilance 16
Biovigilance system
• Not a legislated requirement
but
• Needed to enable sponsors to meet their biovigilance responsibilities including
– routine biovigilance
– additional biovigilance specified in the Risk Management Plan (RMP)
 where an RMP is required
– all traceability and any other requirements specified as conditions of registration
– the critical analysis of adverse events and other safety and quality information
– any activities needed to mitigate an identified safety issue
Biovigilance 17
Traceability
• Sponsor needs to be able to locate and identify a biological during any step in the
process from donor to recipient (including disposal)
• The donor, tissue establishments, manufacturing facilities, medical facilities and
recipients must all be identifiable
• Traceability also covers the ability to locate and identify all relevant data relating
to products, materials and people that have come into contact with the biological
• Required
– Therapeutic Goods Order No. 87 6(1)
– Class 3 and 4 biologicals (where an RMP is required) - a product specific
condition of registration requires traceability to the recipient
Biovigilance 18
Where to from here?
• Biovigilance guidance – drafting now completed
• The draft guidance was endorsed by the TGA Regulatory Practice Committee (RPC) for
consultation
• Consultation will commence shortly and be in parallel with RMP guidance which has
been revised to include specific biologicals advice
• Will be a public consultation – information on TGA website + invitation
• Consideration of responses  finalisation and publication of final guidance
• Regulatory aspects to be determined
– The equivalent pharmacovigilance guidance is included in the Therapeutic Goods
Regulations 1990
– Conditions of registration
Biovigilance 19
Questions?
Biovigilance 20
Biovigilance

More Related Content

What's hot

TMF PDF.pdf
TMF PDF.pdfTMF PDF.pdf
TMF PDF.pdf
ShaguftaNaaz44
 
Pharmacovigilance overview
Pharmacovigilance overviewPharmacovigilance overview
Pharmacovigilance overview
Sunil Boreddy Rx
 
Fast track drugs - Rapid study and Approval
Fast track drugs - Rapid study and ApprovalFast track drugs - Rapid study and Approval
Fast track drugs - Rapid study and Approval
Debashish Sarkar
 

What's hot (20)

Aggregate Reporting_Pharmacovigilance_Katalyst HLS
Aggregate Reporting_Pharmacovigilance_Katalyst HLSAggregate Reporting_Pharmacovigilance_Katalyst HLS
Aggregate Reporting_Pharmacovigilance_Katalyst HLS
 
TMF PDF.pdf
TMF PDF.pdfTMF PDF.pdf
TMF PDF.pdf
 
Clinical Data Management Plan_Katalyst HLS
Clinical Data Management Plan_Katalyst HLSClinical Data Management Plan_Katalyst HLS
Clinical Data Management Plan_Katalyst HLS
 
Pharmacovigilance overview
Pharmacovigilance overviewPharmacovigilance overview
Pharmacovigilance overview
 
An overview -Pharmacovigilance by Pougang Golmei,m.pharm,RIPANS,Mizoram
An overview -Pharmacovigilance by Pougang Golmei,m.pharm,RIPANS,MizoramAn overview -Pharmacovigilance by Pougang Golmei,m.pharm,RIPANS,Mizoram
An overview -Pharmacovigilance by Pougang Golmei,m.pharm,RIPANS,Mizoram
 
Pharmacovigilance
PharmacovigilancePharmacovigilance
Pharmacovigilance
 
Pharmacoepidemiology
PharmacoepidemiologyPharmacoepidemiology
Pharmacoepidemiology
 
Pharmacovigilance
PharmacovigilancePharmacovigilance
Pharmacovigilance
 
Archiving of clincial study records.pptx
Archiving of clincial study records.pptxArchiving of clincial study records.pptx
Archiving of clincial study records.pptx
 
Oracle Clinical Overview_Katalyst HLS
Oracle Clinical Overview_Katalyst HLSOracle Clinical Overview_Katalyst HLS
Oracle Clinical Overview_Katalyst HLS
 
Pharmacovigilance Overview
Pharmacovigilance OverviewPharmacovigilance Overview
Pharmacovigilance Overview
 
Fda med watch
Fda med watchFda med watch
Fda med watch
 
Literature searches in Pharmacovigilance
Literature searches in PharmacovigilanceLiterature searches in Pharmacovigilance
Literature searches in Pharmacovigilance
 
Schedule Y by akshdeep sharma
Schedule Y by akshdeep sharmaSchedule Y by akshdeep sharma
Schedule Y by akshdeep sharma
 
Investigator Site File (ISF) / Trial Master file in trial (TMF)
Investigator Site File (ISF) / Trial Master file in trial (TMF)Investigator Site File (ISF) / Trial Master file in trial (TMF)
Investigator Site File (ISF) / Trial Master file in trial (TMF)
 
Case Report Form (CRF)
Case Report Form (CRF)Case Report Form (CRF)
Case Report Form (CRF)
 
Pharmacovigilance
PharmacovigilancePharmacovigilance
Pharmacovigilance
 
Prescription event monitoring
Prescription event monitoringPrescription event monitoring
Prescription event monitoring
 
Clinical Data Management
Clinical Data ManagementClinical Data Management
Clinical Data Management
 
Fast track drugs - Rapid study and Approval
Fast track drugs - Rapid study and ApprovalFast track drugs - Rapid study and Approval
Fast track drugs - Rapid study and Approval
 

Viewers also liked

Viewers also liked (20)

This year's highlights and what's ahead for 2017
This year's highlights and what's ahead for 2017This year's highlights and what's ahead for 2017
This year's highlights and what's ahead for 2017
 
Pharmacovigilance - a regulator's perspective
Pharmacovigilance - a regulator's perspectivePharmacovigilance - a regulator's perspective
Pharmacovigilance - a regulator's perspective
 
Presentation: What's trending in medicines regulation? A January 2017 reflection
Presentation: What's trending in medicines regulation? A January 2017 reflectionPresentation: What's trending in medicines regulation? A January 2017 reflection
Presentation: What's trending in medicines regulation? A January 2017 reflection
 
17. Gino Grampp - Amgen
17. Gino Grampp - Amgen17. Gino Grampp - Amgen
17. Gino Grampp - Amgen
 
Medicines Safety in WHO: promoting best practices in Pharmacovigilance
Medicines Safety in WHO: promoting best practices in PharmacovigilanceMedicines Safety in WHO: promoting best practices in Pharmacovigilance
Medicines Safety in WHO: promoting best practices in Pharmacovigilance
 
Pharmacovigilance for biotherapeutics: Partnering for patient safety
Pharmacovigilance for biotherapeutics: Partnering for patient safetyPharmacovigilance for biotherapeutics: Partnering for patient safety
Pharmacovigilance for biotherapeutics: Partnering for patient safety
 
Epidemiological situations: Compliance to Therapeutic Goods Order
Epidemiological situations: Compliance to Therapeutic Goods Order Epidemiological situations: Compliance to Therapeutic Goods Order
Epidemiological situations: Compliance to Therapeutic Goods Order
 
TGA Presentation: What’s happening in regulation?
TGA Presentation: What’s happening in regulation?TGA Presentation: What’s happening in regulation?
TGA Presentation: What’s happening in regulation?
 
Better medicine labels: New requirements under TGOs 91 and 92
Better medicine labels: New requirements under TGOs 91 and 92Better medicine labels: New requirements under TGOs 91 and 92
Better medicine labels: New requirements under TGOs 91 and 92
 
Regulatory Reform - an update
Regulatory Reform - an updateRegulatory Reform - an update
Regulatory Reform - an update
 
Update and Variations to Biologicals
Update and Variations to BiologicalsUpdate and Variations to Biologicals
Update and Variations to Biologicals
 
Single use technology: a regulatory perspective
Single use technology: a regulatory perspectiveSingle use technology: a regulatory perspective
Single use technology: a regulatory perspective
 
24. Dr. Thomas Schreitmueller - F. Hoffman-La Roche (on behalf of IFPMA)
24. Dr. Thomas Schreitmueller - F. Hoffman-La Roche (on behalf of IFPMA)24. Dr. Thomas Schreitmueller - F. Hoffman-La Roche (on behalf of IFPMA)
24. Dr. Thomas Schreitmueller - F. Hoffman-La Roche (on behalf of IFPMA)
 
Updating medicine ingredient names: International harmonisation of ingredient...
Updating medicine ingredient names: International harmonisation of ingredient...Updating medicine ingredient names: International harmonisation of ingredient...
Updating medicine ingredient names: International harmonisation of ingredient...
 
Consultation on “Guidance on variations to biologicals included in the Register”
Consultation on “Guidance on variations to biologicals included in the Register”Consultation on “Guidance on variations to biologicals included in the Register”
Consultation on “Guidance on variations to biologicals included in the Register”
 
Regulation of Nanomedicines by the Therapeutic Goods Administration
Regulation of Nanomedicines by the Therapeutic Goods AdministrationRegulation of Nanomedicines by the Therapeutic Goods Administration
Regulation of Nanomedicines by the Therapeutic Goods Administration
 
Prescription Medicines MMDR Reforms
Prescription Medicines MMDR ReformsPrescription Medicines MMDR Reforms
Prescription Medicines MMDR Reforms
 
Presentation: Increased reports of allergic adverse events following 2015 inf...
Presentation: Increased reports of allergic adverse events following 2015 inf...Presentation: Increased reports of allergic adverse events following 2015 inf...
Presentation: Increased reports of allergic adverse events following 2015 inf...
 
16. Malin Fladvad - Uppsala Monitoring Centre
16. Malin Fladvad - Uppsala Monitoring Centre16. Malin Fladvad - Uppsala Monitoring Centre
16. Malin Fladvad - Uppsala Monitoring Centre
 
Expert review of medicines and medical devices regulation: Prescription medic...
Expert review of medicines and medical devices regulation: Prescription medic...Expert review of medicines and medical devices regulation: Prescription medic...
Expert review of medicines and medical devices regulation: Prescription medic...
 

Similar to Biovigilance

Pharmacovigilance in Australia
Pharmacovigilance in AustraliaPharmacovigilance in Australia
Pharmacovigilance in Australia
Saeeda Hasan
 
METHODS OF POST MARKETING SURVEILLANCE
METHODS OF POST MARKETING SURVEILLANCEMETHODS OF POST MARKETING SURVEILLANCE
METHODS OF POST MARKETING SURVEILLANCE
Dr Arathy R Nath
 

Similar to Biovigilance (20)

TGA presentation: Postmarket Monitoring
TGA presentation: Postmarket MonitoringTGA presentation: Postmarket Monitoring
TGA presentation: Postmarket Monitoring
 
Postmarket monitoring of therapeutic goods in Australia
Postmarket monitoring of therapeutic goods in AustraliaPostmarket monitoring of therapeutic goods in Australia
Postmarket monitoring of therapeutic goods in Australia
 
The regulation of biologicals in Australia
The regulation of biologicals in AustraliaThe regulation of biologicals in Australia
The regulation of biologicals in Australia
 
FDA 2013 Clinical Investigator Training Course: Biosimilar Biological Products
FDA 2013 Clinical Investigator Training Course: Biosimilar Biological ProductsFDA 2013 Clinical Investigator Training Course: Biosimilar Biological Products
FDA 2013 Clinical Investigator Training Course: Biosimilar Biological Products
 
Presentation: Increasing post-market vigilance requirements for medical devices
Presentation: Increasing post-market vigilance requirements for medical devicesPresentation: Increasing post-market vigilance requirements for medical devices
Presentation: Increasing post-market vigilance requirements for medical devices
 
Module 3 requirements for Biologics (peptide/protein medicines)
Module 3 requirements for Biologics (peptide/protein medicines)Module 3 requirements for Biologics (peptide/protein medicines)
Module 3 requirements for Biologics (peptide/protein medicines)
 
TGA Presentation: Biologicals framework updates
TGA Presentation: Biologicals framework updatesTGA Presentation: Biologicals framework updates
TGA Presentation: Biologicals framework updates
 
GPs’ role in quality use of medicines in Australia
GPs’ role in quality use of medicines in AustraliaGPs’ role in quality use of medicines in Australia
GPs’ role in quality use of medicines in Australia
 
FDA 2013 Clinical Investigator Training Course: Safety Assessment in Clinical...
FDA 2013 Clinical Investigator Training Course: Safety Assessment in Clinical...FDA 2013 Clinical Investigator Training Course: Safety Assessment in Clinical...
FDA 2013 Clinical Investigator Training Course: Safety Assessment in Clinical...
 
Dcgi adverse event
Dcgi adverse eventDcgi adverse event
Dcgi adverse event
 
Pharmacovigilance overview
Pharmacovigilance overviewPharmacovigilance overview
Pharmacovigilance overview
 
Regulatory guidance and guidelines for filing and approval for biologics
Regulatory guidance and guidelines for filing and approval for biologicsRegulatory guidance and guidelines for filing and approval for biologics
Regulatory guidance and guidelines for filing and approval for biologics
 
Presentation: Therapeutic Goods Administration: An introduction to the work o...
Presentation: Therapeutic Goods Administration: An introduction to the work o...Presentation: Therapeutic Goods Administration: An introduction to the work o...
Presentation: Therapeutic Goods Administration: An introduction to the work o...
 
Regulation of cell and tissue therapies and clinical research in Australia
Regulation of cell and tissue therapies and clinical research in AustraliaRegulation of cell and tissue therapies and clinical research in Australia
Regulation of cell and tissue therapies and clinical research in Australia
 
Pharmacovigilance in Australia
Pharmacovigilance in AustraliaPharmacovigilance in Australia
Pharmacovigilance in Australia
 
Pharmacovigilance in Australia
Pharmacovigilance in AustraliaPharmacovigilance in Australia
Pharmacovigilance in Australia
 
Mr. Richard Coulter - Global Antibiotic Regulations
Mr. Richard Coulter - Global Antibiotic RegulationsMr. Richard Coulter - Global Antibiotic Regulations
Mr. Richard Coulter - Global Antibiotic Regulations
 
Safety_Data_Reconciliation_Katalyst HLS
Safety_Data_Reconciliation_Katalyst HLSSafety_Data_Reconciliation_Katalyst HLS
Safety_Data_Reconciliation_Katalyst HLS
 
METHODS OF POST MARKETING SURVEILLANCE
METHODS OF POST MARKETING SURVEILLANCEMETHODS OF POST MARKETING SURVEILLANCE
METHODS OF POST MARKETING SURVEILLANCE
 
Safety monitoring and reporting of adverse events of medical devices national...
Safety monitoring and reporting of adverse events of medical devices national...Safety monitoring and reporting of adverse events of medical devices national...
Safety monitoring and reporting of adverse events of medical devices national...
 

More from TGA Australia

More from TGA Australia (20)

Pharmacovigilance and complementary medicines - Regulatory requirements
Pharmacovigilance and complementary medicines - Regulatory requirementsPharmacovigilance and complementary medicines - Regulatory requirements
Pharmacovigilance and complementary medicines - Regulatory requirements
 
The challenges of regulating direct to consumer digital medical devices
The challenges of regulating direct to consumer digital medical devicesThe challenges of regulating direct to consumer digital medical devices
The challenges of regulating direct to consumer digital medical devices
 
Updates from the Pharmacovigilance and Special Access Branch
Updates from the Pharmacovigilance and Special Access Branch Updates from the Pharmacovigilance and Special Access Branch
Updates from the Pharmacovigilance and Special Access Branch
 
Consumer Medicine Information - Improving the CMI template
Consumer Medicine Information - Improving the CMI templateConsumer Medicine Information - Improving the CMI template
Consumer Medicine Information - Improving the CMI template
 
Regulatory updates from the Complementary and OTC Medicines Branch - Listed m...
Regulatory updates from the Complementary and OTC Medicines Branch - Listed m...Regulatory updates from the Complementary and OTC Medicines Branch - Listed m...
Regulatory updates from the Complementary and OTC Medicines Branch - Listed m...
 
Improved electronic submission methodologies - Challenges and future state
Improved electronic submission methodologies - Challenges and future stateImproved electronic submission methodologies - Challenges and future state
Improved electronic submission methodologies - Challenges and future state
 
Regulation, ethics and reimbursement of novel biological therapies in Austral...
Regulation, ethics and reimbursement of novel biological therapies in Austral...Regulation, ethics and reimbursement of novel biological therapies in Austral...
Regulation, ethics and reimbursement of novel biological therapies in Austral...
 
Updates to Good Manufacturing Practices - Recent, current and future changes
Updates to Good Manufacturing Practices - Recent, current and future changesUpdates to Good Manufacturing Practices - Recent, current and future changes
Updates to Good Manufacturing Practices - Recent, current and future changes
 
Good Clinical Practice Inspections - Consultation to introduce a pilot progra...
Good Clinical Practice Inspections - Consultation to introduce a pilot progra...Good Clinical Practice Inspections - Consultation to introduce a pilot progra...
Good Clinical Practice Inspections - Consultation to introduce a pilot progra...
 
Manufacturing Investigational Medicinal Products - Legislative and GMP requir...
Manufacturing Investigational Medicinal Products - Legislative and GMP requir...Manufacturing Investigational Medicinal Products - Legislative and GMP requir...
Manufacturing Investigational Medicinal Products - Legislative and GMP requir...
 
Update on regulatory reforms from the Scientific Evaluation Branch
Update on regulatory reforms from the Scientific Evaluation BranchUpdate on regulatory reforms from the Scientific Evaluation Branch
Update on regulatory reforms from the Scientific Evaluation Branch
 
Update on regulatory reforms from the Scientific Evaluation Branch
Update on regulatory reforms from the Scientific Evaluation BranchUpdate on regulatory reforms from the Scientific Evaluation Branch
Update on regulatory reforms from the Scientific Evaluation Branch
 
Reporting of Medicine Shortages
Reporting of Medicine ShortagesReporting of Medicine Shortages
Reporting of Medicine Shortages
 
Regulatory updates from the TGA Medical Devices Branch - Part 1
Regulatory updates from the TGA Medical Devices Branch - Part 1Regulatory updates from the TGA Medical Devices Branch - Part 1
Regulatory updates from the TGA Medical Devices Branch - Part 1
 
Regulatory updates from the TGA Medical Devices Branch - Part 2
Regulatory updates from the TGA Medical Devices Branch - Part 2Regulatory updates from the TGA Medical Devices Branch - Part 2
Regulatory updates from the TGA Medical Devices Branch - Part 2
 
SME Assist: Help to navigate the regulatory maze
SME Assist: Help to navigate the regulatory mazeSME Assist: Help to navigate the regulatory maze
SME Assist: Help to navigate the regulatory maze
 
TGA webinar: The Good Manufacturing Practice (GMP) Clearance Framework – an o...
TGA webinar: The Good Manufacturing Practice (GMP) Clearance Framework – an o...TGA webinar: The Good Manufacturing Practice (GMP) Clearance Framework – an o...
TGA webinar: The Good Manufacturing Practice (GMP) Clearance Framework – an o...
 
Presentation: Updates from the Pharmacovigilance and Special Access Branch
Presentation: Updates from the Pharmacovigilance and Special Access BranchPresentation: Updates from the Pharmacovigilance and Special Access Branch
Presentation: Updates from the Pharmacovigilance and Special Access Branch
 
Presentation: The challenges of regulating direct to consumer digital medical...
Presentation: The challenges of regulating direct to consumer digital medical...Presentation: The challenges of regulating direct to consumer digital medical...
Presentation: The challenges of regulating direct to consumer digital medical...
 
TGA Presentation: Therapeutic Goods Advertising Code (No. 2) 2018
TGA Presentation: Therapeutic Goods Advertising Code (No. 2) 2018TGA Presentation: Therapeutic Goods Advertising Code (No. 2) 2018
TGA Presentation: Therapeutic Goods Advertising Code (No. 2) 2018
 

Recently uploaded

Call Girl In Indore 📞9235973566📞 Just📲 Call Inaaya Indore Call Girls Service ...
Call Girl In Indore 📞9235973566📞 Just📲 Call Inaaya Indore Call Girls Service ...Call Girl In Indore 📞9235973566📞 Just📲 Call Inaaya Indore Call Girls Service ...
Call Girl In Indore 📞9235973566📞 Just📲 Call Inaaya Indore Call Girls Service ...
Sheetaleventcompany
 
Call Girl in Chennai | Whatsapp No 📞 7427069034 📞 VIP Escorts Service Availab...
Call Girl in Chennai | Whatsapp No 📞 7427069034 📞 VIP Escorts Service Availab...Call Girl in Chennai | Whatsapp No 📞 7427069034 📞 VIP Escorts Service Availab...
Call Girl in Chennai | Whatsapp No 📞 7427069034 📞 VIP Escorts Service Availab...
amritaverma53
 
Premium Call Girls Dehradun {8854095900} ❤️VVIP ANJU Call Girls in Dehradun U...
Premium Call Girls Dehradun {8854095900} ❤️VVIP ANJU Call Girls in Dehradun U...Premium Call Girls Dehradun {8854095900} ❤️VVIP ANJU Call Girls in Dehradun U...
Premium Call Girls Dehradun {8854095900} ❤️VVIP ANJU Call Girls in Dehradun U...
Sheetaleventcompany
 
Premium Call Girls Nagpur {9xx000xx09} ❤️VVIP POOJA Call Girls in Nagpur Maha...
Premium Call Girls Nagpur {9xx000xx09} ❤️VVIP POOJA Call Girls in Nagpur Maha...Premium Call Girls Nagpur {9xx000xx09} ❤️VVIP POOJA Call Girls in Nagpur Maha...
Premium Call Girls Nagpur {9xx000xx09} ❤️VVIP POOJA Call Girls in Nagpur Maha...
Sheetaleventcompany
 
Difference Between Skeletal Smooth and Cardiac Muscles
Difference Between Skeletal Smooth and Cardiac MusclesDifference Between Skeletal Smooth and Cardiac Muscles
Difference Between Skeletal Smooth and Cardiac Muscles
MedicoseAcademics
 
Gorgeous Call Girls Dehradun {8854095900} ❤️VVIP ROCKY Call Girls in Dehradun...
Gorgeous Call Girls Dehradun {8854095900} ❤️VVIP ROCKY Call Girls in Dehradun...Gorgeous Call Girls Dehradun {8854095900} ❤️VVIP ROCKY Call Girls in Dehradun...
Gorgeous Call Girls Dehradun {8854095900} ❤️VVIP ROCKY Call Girls in Dehradun...
Sheetaleventcompany
 
Goa Call Girl Service 📞9xx000xx09📞Just Call Divya📲 Call Girl In Goa No💰Advanc...
Goa Call Girl Service 📞9xx000xx09📞Just Call Divya📲 Call Girl In Goa No💰Advanc...Goa Call Girl Service 📞9xx000xx09📞Just Call Divya📲 Call Girl In Goa No💰Advanc...
Goa Call Girl Service 📞9xx000xx09📞Just Call Divya📲 Call Girl In Goa No💰Advanc...
Sheetaleventcompany
 
Dehradun Call Girls Service {8854095900} ❤️VVIP ROCKY Call Girl in Dehradun U...
Dehradun Call Girls Service {8854095900} ❤️VVIP ROCKY Call Girl in Dehradun U...Dehradun Call Girls Service {8854095900} ❤️VVIP ROCKY Call Girl in Dehradun U...
Dehradun Call Girls Service {8854095900} ❤️VVIP ROCKY Call Girl in Dehradun U...
Sheetaleventcompany
 

Recently uploaded (20)

Call 8250092165 Patna Call Girls ₹4.5k Cash Payment With Room Delivery
Call 8250092165 Patna Call Girls ₹4.5k Cash Payment With Room DeliveryCall 8250092165 Patna Call Girls ₹4.5k Cash Payment With Room Delivery
Call 8250092165 Patna Call Girls ₹4.5k Cash Payment With Room Delivery
 
Call girls Service Phullen / 9332606886 Genuine Call girls with real Photos a...
Call girls Service Phullen / 9332606886 Genuine Call girls with real Photos a...Call girls Service Phullen / 9332606886 Genuine Call girls with real Photos a...
Call girls Service Phullen / 9332606886 Genuine Call girls with real Photos a...
 
Kolkata Call Girls Naktala 💯Call Us 🔝 8005736733 🔝 💃 Top Class Call Girl Se...
Kolkata Call Girls Naktala  💯Call Us 🔝 8005736733 🔝 💃  Top Class Call Girl Se...Kolkata Call Girls Naktala  💯Call Us 🔝 8005736733 🔝 💃  Top Class Call Girl Se...
Kolkata Call Girls Naktala 💯Call Us 🔝 8005736733 🔝 💃 Top Class Call Girl Se...
 
Bhawanipatna Call Girls 📞9332606886 Call Girls in Bhawanipatna Escorts servic...
Bhawanipatna Call Girls 📞9332606886 Call Girls in Bhawanipatna Escorts servic...Bhawanipatna Call Girls 📞9332606886 Call Girls in Bhawanipatna Escorts servic...
Bhawanipatna Call Girls 📞9332606886 Call Girls in Bhawanipatna Escorts servic...
 
Cardiac Output, Venous Return, and Their Regulation
Cardiac Output, Venous Return, and Their RegulationCardiac Output, Venous Return, and Their Regulation
Cardiac Output, Venous Return, and Their Regulation
 
Call Girl In Indore 📞9235973566📞 Just📲 Call Inaaya Indore Call Girls Service ...
Call Girl In Indore 📞9235973566📞 Just📲 Call Inaaya Indore Call Girls Service ...Call Girl In Indore 📞9235973566📞 Just📲 Call Inaaya Indore Call Girls Service ...
Call Girl In Indore 📞9235973566📞 Just📲 Call Inaaya Indore Call Girls Service ...
 
Independent Bangalore Call Girls (Adult Only) 💯Call Us 🔝 7304373326 🔝 💃 Escor...
Independent Bangalore Call Girls (Adult Only) 💯Call Us 🔝 7304373326 🔝 💃 Escor...Independent Bangalore Call Girls (Adult Only) 💯Call Us 🔝 7304373326 🔝 💃 Escor...
Independent Bangalore Call Girls (Adult Only) 💯Call Us 🔝 7304373326 🔝 💃 Escor...
 
Call Girl in Chennai | Whatsapp No 📞 7427069034 📞 VIP Escorts Service Availab...
Call Girl in Chennai | Whatsapp No 📞 7427069034 📞 VIP Escorts Service Availab...Call Girl in Chennai | Whatsapp No 📞 7427069034 📞 VIP Escorts Service Availab...
Call Girl in Chennai | Whatsapp No 📞 7427069034 📞 VIP Escorts Service Availab...
 
Premium Call Girls Dehradun {8854095900} ❤️VVIP ANJU Call Girls in Dehradun U...
Premium Call Girls Dehradun {8854095900} ❤️VVIP ANJU Call Girls in Dehradun U...Premium Call Girls Dehradun {8854095900} ❤️VVIP ANJU Call Girls in Dehradun U...
Premium Call Girls Dehradun {8854095900} ❤️VVIP ANJU Call Girls in Dehradun U...
 
Call Girls Bangalore - 450+ Call Girl Cash Payment 💯Call Us 🔝 6378878445 🔝 💃 ...
Call Girls Bangalore - 450+ Call Girl Cash Payment 💯Call Us 🔝 6378878445 🔝 💃 ...Call Girls Bangalore - 450+ Call Girl Cash Payment 💯Call Us 🔝 6378878445 🔝 💃 ...
Call Girls Bangalore - 450+ Call Girl Cash Payment 💯Call Us 🔝 6378878445 🔝 💃 ...
 
Premium Call Girls Nagpur {9xx000xx09} ❤️VVIP POOJA Call Girls in Nagpur Maha...
Premium Call Girls Nagpur {9xx000xx09} ❤️VVIP POOJA Call Girls in Nagpur Maha...Premium Call Girls Nagpur {9xx000xx09} ❤️VVIP POOJA Call Girls in Nagpur Maha...
Premium Call Girls Nagpur {9xx000xx09} ❤️VVIP POOJA Call Girls in Nagpur Maha...
 
Difference Between Skeletal Smooth and Cardiac Muscles
Difference Between Skeletal Smooth and Cardiac MusclesDifference Between Skeletal Smooth and Cardiac Muscles
Difference Between Skeletal Smooth and Cardiac Muscles
 
Gorgeous Call Girls Dehradun {8854095900} ❤️VVIP ROCKY Call Girls in Dehradun...
Gorgeous Call Girls Dehradun {8854095900} ❤️VVIP ROCKY Call Girls in Dehradun...Gorgeous Call Girls Dehradun {8854095900} ❤️VVIP ROCKY Call Girls in Dehradun...
Gorgeous Call Girls Dehradun {8854095900} ❤️VVIP ROCKY Call Girls in Dehradun...
 
💰Call Girl In Bangalore☎️63788-78445💰 Call Girl service in Bangalore☎️Bangalo...
💰Call Girl In Bangalore☎️63788-78445💰 Call Girl service in Bangalore☎️Bangalo...💰Call Girl In Bangalore☎️63788-78445💰 Call Girl service in Bangalore☎️Bangalo...
💰Call Girl In Bangalore☎️63788-78445💰 Call Girl service in Bangalore☎️Bangalo...
 
Goa Call Girl Service 📞9xx000xx09📞Just Call Divya📲 Call Girl In Goa No💰Advanc...
Goa Call Girl Service 📞9xx000xx09📞Just Call Divya📲 Call Girl In Goa No💰Advanc...Goa Call Girl Service 📞9xx000xx09📞Just Call Divya📲 Call Girl In Goa No💰Advanc...
Goa Call Girl Service 📞9xx000xx09📞Just Call Divya📲 Call Girl In Goa No💰Advanc...
 
Low Cost Call Girls Bangalore {9179660964} ❤️VVIP NISHA Call Girls in Bangalo...
Low Cost Call Girls Bangalore {9179660964} ❤️VVIP NISHA Call Girls in Bangalo...Low Cost Call Girls Bangalore {9179660964} ❤️VVIP NISHA Call Girls in Bangalo...
Low Cost Call Girls Bangalore {9179660964} ❤️VVIP NISHA Call Girls in Bangalo...
 
Exclusive Call Girls Bangalore {7304373326} ❤️VVIP POOJA Call Girls in Bangal...
Exclusive Call Girls Bangalore {7304373326} ❤️VVIP POOJA Call Girls in Bangal...Exclusive Call Girls Bangalore {7304373326} ❤️VVIP POOJA Call Girls in Bangal...
Exclusive Call Girls Bangalore {7304373326} ❤️VVIP POOJA Call Girls in Bangal...
 
❤️Call Girl Service In Chandigarh☎️9814379184☎️ Call Girl in Chandigarh☎️ Cha...
❤️Call Girl Service In Chandigarh☎️9814379184☎️ Call Girl in Chandigarh☎️ Cha...❤️Call Girl Service In Chandigarh☎️9814379184☎️ Call Girl in Chandigarh☎️ Cha...
❤️Call Girl Service In Chandigarh☎️9814379184☎️ Call Girl in Chandigarh☎️ Cha...
 
Call Girls Shahdol Just Call 8250077686 Top Class Call Girl Service Available
Call Girls Shahdol Just Call 8250077686 Top Class Call Girl Service AvailableCall Girls Shahdol Just Call 8250077686 Top Class Call Girl Service Available
Call Girls Shahdol Just Call 8250077686 Top Class Call Girl Service Available
 
Dehradun Call Girls Service {8854095900} ❤️VVIP ROCKY Call Girl in Dehradun U...
Dehradun Call Girls Service {8854095900} ❤️VVIP ROCKY Call Girl in Dehradun U...Dehradun Call Girls Service {8854095900} ❤️VVIP ROCKY Call Girl in Dehradun U...
Dehradun Call Girls Service {8854095900} ❤️VVIP ROCKY Call Girl in Dehradun U...
 

Biovigilance

  • 1. Biovigilance Dr Bronwen Harvey Director, Signal Investigation Unit Pharmacovigilance and Special Access Branch, TGA Biotherapeutics Association of Australasia 2016 AGM, TGA Workshop & Education Session 13 October 2016
  • 2. Outline • What are biologicals? • Regulatory framework for biologicals • What is biovigilance? • Responsibilities of sponsors of biologicals – reporting adverse events – recalls • Sponsors’ biovigilance systems • TGA process – development of draft guidance, consultation, finalisation of guidance – regulatory aspects • Questions and discussion Biovigilance 1
  • 3. What are biologicals? Short definition = human tissue and cell-derived products Definition of a biological in the TG Act (Part 3-2A–Biologicals) 32A Meaning of biological (1) Subject to subsection (3), a biological is a thing that: (a) either: (i) comprises, contains or is derived from human cells or human tissues; or (ii) is specified under subsection (2); and (b) is represented in any way to be, or is, whether because of the way in which it is presented or for any other reason, likely to be taken to be: (i) for use in the treatment or prevention of a disease, ailment, defect or injury affecting persons; or (ii) for use in making a medical diagnosis of the condition of a person; or (iii) for use in influencing, inhibiting or modifying a physiological process in persons; or (iv) for use in testing the susceptibility of persons to a disease or ailment; or (v) for use in the replacement or modification of parts of the anatomy in persons. [In addition, the Secretary can specify things to be or not to be biologicals by instrument] Biovigilance 2
  • 4. Regulatory framework for biologicals • Provides the legislative basis for the regulation of human tissue and cell-derived products that are supplied in, or exported from, Australia. • Legislation commenced May 2011 – transition period (3 years+) • Information on TGA website at https://www.tga.gov.au/regulatory-framework-biologicals • Australian Regulatory Guidelines for Biologicals at https://www.tga.gov.au/publication/australian- regulatory-guidelines-biologicals-argb • Not biological medicines • Similar, but not identical, to the EMA’s Advanced Therapy Medicinal Products (ATMPs) which are medicines for human use that are based on genes or cells Biovigilance 3
  • 5. What is biovigilance? • The science and activities relating to the detection, assessment, understanding and prevention of adverse events or any other problems related to biologicals • Therapeutic product vigilance in Australia  Pharmacovigilance  Medical devices vigilance  Biovigilance • Includes quality issues • Other terms - post-market monitoring / surveillance • Systematic collection and analysis of information to improve patient safety Biovigilance 4
  • 6. Responsibilities of sponsors of biologicals • Therapeutic Goods Act 1989 and Therapeutic Goods Regulations 1990 • Sponsors of biological products on the Australian Register of Therapeutic Goods (ARTG) must report to the TGA  Serious threat to public health = 48 hours  Serious adverse event = 10 calendar days  Near serious adverse event = 30 calendar days • This terminology used as biologicals legislation was based on devices legislation • All classes of biologicals • Uniform Recall Procedure for Therapeutic Goods  Recalls, quality defects, contaminated biologicals = as soon as possible Biovigilance 5
  • 7. Biovigilance guidance • Draft guidance has been developed based on the TGA pharmacovigilance and medical device vigilance guidance • Also based on relevant pharmacovigilance guidance, standards and terminology – European Medicine Agency (EMA) Good Pharmacovigilance Practice (GVP) – International Conference on Harmonisation of Technical Requirements Technical Requirements for Pharmaceuticals for Human Use (ICH) Biovigilance 6
  • 8. Adverse events (1) • Any undesirable medical event that occurs in temporal relationship with (during or after) the use of a biological product – symptom, sign (e.g. abnormal laboratory finding), disease or injury – at least a reasonable possibility of a causal relationship between the use of the biological and the event • Serious adverse event – an event or occurrence that led to a death or serious deterioration in the state of health of a patient, a user of the biological or another person • Near serious adverse event – an event or occurrence that, if it occurred again, might lead to the death or serious deterioration in the state of health of a patient, a user of the biological or another person Biovigilance 7
  • 9. Adverse events (2) • AEs may relate to the biological itself or any aspect of the biological – Solutions – Excipients – other substances or materials – Packaging – delivery systems Biovigilance 8
  • 10. Adverse events (3) • Potential for AEs depends on – origin of the biological (autologous or allogeneic) – ability of cells constituting a biological to proliferate or differentiate – ability of the biological to initiate an immune response – life span of the biological in vivo – site and mode of administration – type and level of cell manipulation during production – storage time and conditions – out-of-specification findings identified during in-process testing of the biological Biovigilance 9
  • 11. Serious adverse events (SAEs) • An adverse event for which one or more of the following is true – results in death – is life-threatening – requires inpatient hospitalisation – prolongs existing hospitalisation – results in persistent or significant disability or incapacity, including permanent impairment of a body function or permanent damage to a body structure – necessitates medical or surgical intervention to prevent permanent impairment of a body function or permanent damage to a body structure – is a congenital anomaly or birth defect – is a medically important event Biovigilance 10
  • 12. How to report adverse events • Minimum data for a valid report – an identifiable patient (but do not send name to the TGA – one or more suspected biological or delivery system or other aspect of a biological – one or more suspected adverse events (events with a reasonable possibility of causal relationship) – one or more identifiable reporters • Only adverse events that have occurred in Australia • Provide as much information as possible to facilitate assessment of the AE • Range of reporting formats available, including direct data entry online – More information on TGA website at https://www.tga.gov.au/reporting-problems – Will develop specific formats for biologicals – currently use either medicines or medical devices reporting processes Biovigilance 11
  • 13. Examples • Some reports of tissue related adverse events received over the past 3 years – Pulmonary heart valve – leaflet tear and bleeding – Heart valve – sterility concerns – recipient had an infection – Bone (femoral head) – several reports relating to new information about the donor such as malignancy Biovigilance 12
  • 14. Serious threat to public health • Any identified safety issue which may change the benefit-risk assessment of the product and require action to eliminate or reduce that risk, such as – a report of an unexpected or previously unknown serious or near serious adverse event – a change in the nature, severity or frequency of expected (known) adverse events – the identification of previously unknown risk factors – the transmission of an infectious agent, including reactivation of any viral vector – a signal of a possible teratogenic effect – a signal of possible tumorigenicity – unexpected lack of efficacy – issues related to the raw materials used in the biological – issues related to the delivery system used for the biological – issues due to misinformation in the product documentation – issues related to use outside the approved indication or intended use Biovigilance 13
  • 15. How to report a serious threat to public health • In writing and sent by email to the Signal Investigation Coordinator (si.coordinator@tga.gov.au) – Subject line = ‘Urgent – serious threat to public health – [descriptor: name or number of biological, name of sponsor, or some other descriptor]’ – describe the evidence for the threat – indicate the action that the sponsor is proposing to take to eliminate or reduce the risk  the action may relate to conditions of inclusion in the ARTG including amendments to the label or the product information or any other change – clearly identify the person in Australia who is taking responsibility on behalf of the sponsor for the accuracy and veracity of the information in the report – include contact details of the person reporting on behalf of the sponsor, preferably the nominated biovigilance contact person Biovigilance 14
  • 16. Recalls and quality issues • Notify suspected or confirmed quality defects and contaminated or counterfeit biological products to the TGA with the least possible delay – Uniform Recall Procedure for Therapeutic Goods (URPTG)  New version will include biologicals • May be necessary to implement urgent measures to protect public health – for tissues usually “Hazard Alerts” but may involve a recall • Use the Human blood and tissues recall report form or phone TGA Recalls on 1800 020 512 – see Contact details for enquiries about product recalls on the TGA website at https://www.tga.gov.au/product-recalls#contacts Biovigilance 15
  • 17. System for Australian Recall Actions (SARA) - Biologicals Recall action commencement date Product name / description Reason for recall action Recall action 17/06/2014 Pulmonary Valve Allograft Staph epidermis isolated from nutrient broth Hazard Alert 24/04/2014 Corneo-scleral Disc (Normothermic) Potentially untraceable microbiology results Hazard Alert 31/05/2013 Bone Fragments - Milled irradiated femoral head At 2nd donation, donor found to have mantle cell lymphoma Hazard Alert 17/04/2013 Pulmonary Valve Transplant Positive microbiological culture from implant tissue culture Hazard Alert 19/03/2013 RegenerOss Allograft Block Max/Mand Blocks Assays used to test donors for HBsAG and Hep C not licensed for donor testing Hazard Alert 1/03/2013 Bone Fragments - Milled irradiated femoral head Donor melanoma removed 10 months after donation Hazard Alert 15/02/2013 Bone Unprocessed - Whole femoral head non-irradiated allograft Donor diagnosed with oesophageal cancer Hazard Alert 22/01/2013 Corneal Grafts Multiple myeloma found later in bones from same donor Hazard Alert 8/01/2013 QHVB Pulmonary Allograft Conduit (Human cardiovascular tissue) Retained samples showed positive microbial growth Hazard Alert Biovigilance 16
  • 18. Biovigilance system • Not a legislated requirement but • Needed to enable sponsors to meet their biovigilance responsibilities including – routine biovigilance – additional biovigilance specified in the Risk Management Plan (RMP)  where an RMP is required – all traceability and any other requirements specified as conditions of registration – the critical analysis of adverse events and other safety and quality information – any activities needed to mitigate an identified safety issue Biovigilance 17
  • 19. Traceability • Sponsor needs to be able to locate and identify a biological during any step in the process from donor to recipient (including disposal) • The donor, tissue establishments, manufacturing facilities, medical facilities and recipients must all be identifiable • Traceability also covers the ability to locate and identify all relevant data relating to products, materials and people that have come into contact with the biological • Required – Therapeutic Goods Order No. 87 6(1) – Class 3 and 4 biologicals (where an RMP is required) - a product specific condition of registration requires traceability to the recipient Biovigilance 18
  • 20. Where to from here? • Biovigilance guidance – drafting now completed • The draft guidance was endorsed by the TGA Regulatory Practice Committee (RPC) for consultation • Consultation will commence shortly and be in parallel with RMP guidance which has been revised to include specific biologicals advice • Will be a public consultation – information on TGA website + invitation • Consideration of responses  finalisation and publication of final guidance • Regulatory aspects to be determined – The equivalent pharmacovigilance guidance is included in the Therapeutic Goods Regulations 1990 – Conditions of registration Biovigilance 19